Last update Nov. 22, 2022

Foscarnet Sodium

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

It is a non-nucleoside pyrophosphate analog active against herpesviruses. It is used for the treatment of cytomegalovirus retinitis in patients with AIDS and for aciclovir-resistant herpes simplex y varicella-zoster infections in immunocompromised patients. Intravenous administration every 12 hours for 2 to 3 weeks.

At the date of the last update, we found no published data on its excretion in breast milk.

Its pharmacokinetic data (low molecular weight and low percentage of plasma protein binding) makes it likely that significant amounts will pass into breast milk.

Its very low oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.

Common side effects are kidney failure, which can be severe, and anemia.

Alternatives

  • Acyclovir; Aciclovir ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ganciclovir (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Foscarnet Sodium in other languages or writings:

Group

Foscarnet Sodium belongs to this group or family:

Tradenames

Main tradenames from several countries containing Foscarnet Sodium in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 12 - 21 %
Molecular weight 300 daltons
Protein Binding 14 - 17 %
VD 0.5 ± 0.2 l/Kg
Tmax 0.01 hours
3.3 - 6.8 hours

References

  1. AEMPS. Foscarnet. Ficha técnica. 2022 Full text (in our servers)
  2. Clinigen H. Foscarnet. Drug Summary. 2011 Full text (in our servers)

Total visits

3,821

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM